Therefore, given the high discriminatory function of circulating CXCL10 and OPN levels, these biomarkers may be of value clinically to identify patients early in NAFLD pathogenesis and perhaps considered for screening populations where widespread imaging is not available. This evidence concerns the gene CXCL10 and metabolic dysfunction-associated steatotic liver disease.